RE T2* MRI sequences are sensitive to tiny areas of previous bleeding (termed cerebral microbleeds [CMBs]) 1 due to the paramagnetic effects of blood degradation products including oxyhemoglobin and hemosiderin. CMBs are common and may be a prognostic marker of recurrent intracerebral hemorrhage, 2 including antithrombotic related hemorrhage. 3 Studies suggest that the chronic accumulation of CMBs may have an effect on anatomically distributed cerebral functions including cognition. 4 As microbleeds cause focal damage to the brain tissue, 5 acutely developing microbleeds might be expected to cause focal symptoms. We report 2 cases of acute focal neurologic symptoms and clinical signs that in each case appeared to be due to a CMB.
the same day, he was hypertensive (blood pressure [BP] 210/92 mm Hg) and had reduced cold and pain sensation in the left maxillary and mandibular territory of the left V cranial nerve and the lateral aspect of the left forearm. MRI and magnetic resonance angiography carried out on the same day revealed a single focus of susceptibility artifact within the right inferolateral thalamus, consistent with a CMB (figure 1B). No other CMBs were seen elsewhere in the cerebral hemispheres or brainstem (figure e-3). His BP gradually and spontaneously reduced to 133/63 mm Hg. The paraesthesia resolved over 72 hours.
DISCUSSION
In each case, the lesions fulfilled the radiologic criteria proposed for CMBs: they were rounded, homogeneous, small areas of low signal seen well on GRE T2*-weighted imaging but not other sequences, and were more than half surrounded by brain parenchyma. The lesions were not suggestive of mimics (e.g., calcium or iron deposition, flow voids from pial blood vessels, or partial volume artifact). 6 There were no associated changes on other MRI sequences in the same regions (figures e-1 and e-3) and the lesions lacked the characteristic heterogeneous appearance of a cavernous malformation.
A limitation of these 2 cases is that we do not have MRI scans shortly preceding their clinical presentation to confirm that the CMB is acutely responsible for their clinical syndrome. However, in each case, the CMB was found in a location typical for the clinical syndrome. In case 1, the CMB was in the pons adjacent to the facial nucleus, correlating with the clinical presentation. In case 2, the CMB was found in the inferolateral thalamus; lesions in this region typically cause hemisensory paraesthesias in cheiro-oral or pseudoradicular distribution similar to the case reported here.
In case 1, the fainter appearance of the susceptibility artifact on follow-up MRI at 5 months is likely due to technical factors rather than resolution of the lesion as CMBs typically persist for months and years. 6 Poorly controlled hypertension has been associated with the development of new CMBs 7 : it is noteworthy that both patients were severely hypertensive on presentation, which may have contributed to acute CMB development.
A previous report suggested that a CMB could cause an acute stroke syndrome 8 ; a patient with internuclear ophthalmoplegia was found to have a CMB in the medial lemniscus. However, in this report, the MRI was delayed for several months, with evidence of multiple lacunar infarcts, making it difficult to confirm that the CMB was the cause of the acute syndrome. In contrast, our cases were imaged within hours, allowing us to rule out acute ischemia and making any explanation other than the CMBs less likely.
Identifying CMBs as a cause of acute stroke syndromes using MRI may be useful, although it is difficult to be certain of the age of any CMBs detected. Whether patients with stroke syndromes attributed to CMBs should subsequently receive thrombolysis and antithrombotic treatment is unclear, but these treatments would be expected to aggravate any acute bleeding. Recent studies suggest a higher risk of intracerebral hemorrhage with antithrombotics in patients with CMBs, particularly if they are numerous and in a lobar distribution. 3, 9 These 2 cases demonstrate the usefulness of GRE T2* MRI in the acute investigation of a TIA or stroke, and challenge the traditional view that CMBs are clinically silent. Further studies are required to determine how often CMBs underlie acute stroke presentations, and whether they correlate with specific syndromes.
